<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00382889</url>
  </required_header>
  <id_info>
    <org_study_id>MC/PR/1401/001/01</org_study_id>
    <nct_id>NCT00382889</nct_id>
  </id_info>
  <brief_title>As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma</brief_title>
  <official_title>Multinational, Double Blind, Randomised, Parallel Group Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate 250 mg Combined With Salbutamol 100 mg in the Treatment of Patients With Mild Persistent Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <brief_summary>
    <textblock>
      The aim of this study is to reveal that inhaled corticosteroid therapy combined with a&#xD;
      short-acting beta2- agonist given on a symptom driven basis is as effective as traditional&#xD;
      asthma therapy.&#xD;
&#xD;
      Thus, three advantages will be achieved:&#xD;
&#xD;
        1. better compliance with treatment since patients will most likely have to administer the&#xD;
           treatment less frequently,&#xD;
&#xD;
        2. maximum pharmacological effect with the least amount of drug and&#xD;
&#xD;
        3. less economic burden on health care providers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is widely recognised as a chronic inflammatory disorder of the airways. The 1997&#xD;
      American National Heart Lung and Blood Institute (NHLBI) Guidelines states that a firm&#xD;
      scientific basis exists to indicate that asthma results from complex interactions among&#xD;
      inflammatory cells, mediators and the cells and tissues resident in the airways.&#xD;
&#xD;
      Despite the existence of effective therapy people still die from asthma. It is pertinent to&#xD;
      state that the clinical effect of a drug is not only dependent on the specific action of the&#xD;
      drug, but also on the patient's way of using it. Therefore, compliance is an important factor&#xD;
      especially for chronic disorders such as asthma. Indeed, non compliance with asthma therapy&#xD;
      is a serious problem. It has been reported that drug side effects, lifestyle, social and&#xD;
      economic factors, method of drug delivery and dosing are factors that contribute to poor&#xD;
      compliance. The consequences of poor compliance lead to increased morbidity due to increased&#xD;
      symptoms and asthma exacerbation.&#xD;
&#xD;
      The NHLBI Guidelines recommend daily treatment for patients with mild persistent asthma with&#xD;
      inhaled glucocorticoids (200-500mcg/die) and short-acting bronchodilators as needed but no&#xD;
      more than 3-4 times a day.&#xD;
&#xD;
      Comparisons: beclomethasone dipropionate 250 mg combined with salbutamol 100 mg &quot;as needed&quot;,&#xD;
      vs salbutamol 100 mg alone &quot;as needed&quot;, vs beclomethasone 250 mg twice a day plus salbutamol&#xD;
      100 mg &quot;as needed&quot; and vs beclomethasone dipropionate 250 mg combined with salbutamol 100 mg&#xD;
      twice a day plus salbutamol 100 mg &quot;as needed&quot;, in the treatment of patients with mild&#xD;
      persistent asthma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date>September 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome for comparison across treatment groups was the mean value of morning PEF measured during the last 2 weeks of treatment (weeks 23-24)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of exacerbations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first severe exacerbation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of asthma symptoms (symptom scores)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for short acting b2 agonists</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of respiratory parameters (FEV1, PEF, FVC, FEV1/FVC, FEF25-75) immediately before and 30 min after a test with a short-acting b2 agonist</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evening PEF</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diurnal variability of PEF</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal asthma (nocturnal awakening because of asthma)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nights and days without asthma symptoms (score 0)</measure>
  </secondary_outcome>
  <enrollment>480</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beclomethasone/salbutamol combination</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beclomethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salbutamol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of mild persistent asthma as defined by NHLBI/WHO 97; for at least&#xD;
             6 months;&#xD;
&#xD;
          -  FEV1 ³ 75% of predicted normal value;&#xD;
&#xD;
          -  Positive response to the reversibility test to b2 agonist, defined as an increase &gt;&#xD;
             12% in the FEV1 measured 30 minutes following 2 puffs (2x100mg) of inhaled Salbutamol&#xD;
             spray, or positive methacholine challenge (PC20&lt;8mg/ml or PD20&lt;1 mg) within the&#xD;
             previous 6 months;&#xD;
&#xD;
          -  Stable asthma. Asthma is defined stable if none of the following occurred during the&#xD;
             last 14 days of the run-in period: diurnal variation of more than 20% in PEF on 2&#xD;
             consecutive days; use of four or more inhalations of b2 agonist per day on two&#xD;
             consecutive days; need the use of oral corticosteroids;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COPD as defined by the ERS - Consensus Statement;&#xD;
&#xD;
          -  Patients with more than 10 packs/year of cigarettes history and current smokers;&#xD;
&#xD;
          -  History of near fatal asthma and/or admission in intensive care unit because of&#xD;
             asthma;&#xD;
&#xD;
          -  One severe exacerbation during the run-in period;&#xD;
&#xD;
          -  Three or more courses of oral corticosteroids or hospitalisation for asthma during the&#xD;
             previous 1 year;&#xD;
&#xD;
          -  Patients treated with more than 500 mcg/day of beclomethasone or equivalent for more&#xD;
             than 6 months in the previous last year;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo M Fabbri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica di Malattie dell'Apparato Respiratorio, Dipartimento di Oncologia, Ematologia e Pneumologia, Università di Modena e Reggio Emilia, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ambulance for pediatrics and Pneumology</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmologisches Zentrum Der Stadt Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. di Pneumologia - Osp. Tommaselli</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuove Cliniche Arcispedale S.Anna</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIMI - Dip. Medicina Interna - Univ. di Genova - clinica di malattie apparato respiratorio e allergologico</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di scienze mediche oncologiche e radiologiche - sez. malattie apparato respiratorio</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. di Padova - Dipartimento di medicina ambientale e sanità pubblica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Fisiopatologia Respiratoria CNR - Ospedale Cervello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Pneumologica padiglione Rasori - Univ. di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Malattie dell'Apparato Respiratorio dell'Univ. di Pavia - Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reparto Fisiologia Respiratoria - dip. Cardiotoracico - Ospedale Cisanello</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outpatient Clinic of Internal Diseases and Allergology</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialist Group Medex</name>
      <address>
        <city>Bielsko Biala</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Internal Diseases Atopia Al.</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonologic Clinic - Poludnie os. Krakowiakòw</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Pneumology and Allergology</name>
      <address>
        <city>Lòdz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Tubercolosis and Lung Diseases</name>
      <address>
        <city>Lòdz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Pneumology - Institute of Internal Medicine of Medical Academy</name>
      <address>
        <city>Lódz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Occupational Medicine - Clinic of Occupational Disesase</name>
      <address>
        <city>Lódz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Infection Diseases and Allergology - Central Clinical Hospital of Military Medical Academy</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Pneumology and Allergology A.M.</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Pneumology and Allergology of Medical Academy</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.General de Vic, Servicio de Neumologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Matarò</name>
      <address>
        <city>Mataro</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, Crimi N, Vignola AM, Morelli P, Nicolini G, Fabbri LM; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007 May 17;356(20):2040-52.</citation>
    <PMID>17507703</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 29, 2006</study_first_submitted>
  <study_first_submitted_qc>September 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2006</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <keyword>Anti-Asthmatic Agents</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>symptom-driven</keyword>
  <keyword>beclomethasone</keyword>
  <keyword>salbutamol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

